Continue to site >
Trending ETFs

Name

Price

Aum/Mkt Cap

YIELD

Exp Ratio

Watchlist

$113.03

$791 M

0.12%

$0.14

0.98%

Vitals

YTD Return

5.3%

1 yr return

5.1%

3 Yr Avg Return

-8.5%

5 Yr Avg Return

-7.3%

Net Assets

$791 M

Holdings in Top 10

52.9%

52 WEEK LOW AND HIGH

$112.9
$87.97
$116.81

Expenses

OPERATING FEES

Expense Ratio 0.98%

SALES FEES

Front Load 5.50%

Deferred Load N/A

TRADING FEES

Turnover 47.30%

Redemption Fee N/A


Min Investment

Standard (Taxable)

$1,000

IRA

$250


Fund Classification

Fund Type

Open End Mutual Fund


Name

Price

Aum/Mkt Cap

YIELD

Exp Ratio

Watchlist

$113.03

$791 M

0.12%

$0.14

0.98%

FBDIX - Profile

Distributions

  • YTD Total Return 5.3%
  • 3 Yr Annualized Total Return -8.5%
  • 5 Yr Annualized Total Return -7.3%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.58%
DIVIDENDS
  • Dividend Yield 0.1%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Franklin Biotechnology Discovery Fund
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    Sep 15, 1997
  • Shares Outstanding
    6843902
  • Share Class
    A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Evan McCulloch

Fund Description

Under normal market conditions, the Fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The Fund predominantly invests in equity securities. For the Fund’s investment purposes, a biotechnology company or discovery research firm is one that has at least 50% of its earnings derived from biotechnology activities, or at least 50% of its assets devoted to such activities, based on the company’s most recent fiscal year. Discovery research firms are in the early stages of drug research. Biotechnology activities are research, development, manufacture, and distribution of various biotechnological or biomedical products, services, and processes. This may include companies involved with genomics, genetic engineering, and gene therapy. It also includes companies involved in the application and development of biotechnology in areas such as health care, pharmaceuticals, and agriculture. In addition to its investments in biotechnology companies, the Fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. The Fund is a "non-diversified" fund, which means it generally invests a greater portion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.

The Fund may invest a substantial portion of its assets in equity securities of smaller capitalization companies, which are generally companies with market capitalizations of less than $2 billion at the time of the Fund’s investment.

The Fund anticipates that, under normal conditions, it will invest more of its assets in U.S. securities than in securities of any other single country. It is currently anticipated that the Fund’s investments in foreign securities will not exceed 20% of its total assets. The Fund may buy foreign securities that are traded in the U.S. or in foreign markets, as well as American, European, and Global Depositary Receipts.

The investment manager is a research driven, fundamental investor, pursuing a growth strategy. As a "bottom-up" investor focusing primarily on individual securities, the investment manager seeks companies that have identifiable drivers of future earnings growth and that present, in the investment manager's opinion, the best trade-off between that potential earnings growth, business and financial risk, and valuation. Also, in seeking sustainable growth characteristics, the investment manager looks for companies that it believes can produce sustainable earnings growth and cash flow growth or the potential to generate income.

Read More

FBDIX - Performance

Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD 5.3% -25.6% 23.4% 19.34%
1 Yr 5.1% -26.5% 26.1% 19.76%
3 Yr -8.5%* -18.9% 19.7% 92.26%
5 Yr -7.3%* -15.1% 15.3% 88.81%
10 Yr 2.2%* -5.7% 16.4% 75.70%

* Annualized

Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2022 -12.8% -53.9% 11.7% 51.50%
2021 -15.3% -22.3% 18.5% 97.58%
2020 4.3% -4.7% 41.4% 54.84%
2019 5.4% -10.2% 13.1% 31.65%
2018 -4.0% -5.7% 26.9% 91.73%

Total Return Ranking - Trailing

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
YTD 5.3% -41.2% 23.4% 19.34%
1 Yr 5.1% -28.5% 28.3% 24.58%
3 Yr -8.5%* -18.9% 19.7% 92.12%
5 Yr -7.3%* -15.1% 15.3% 90.28%
10 Yr 4.9%* -5.7% 16.4% 68.52%

* Annualized

Total Return Ranking - Calendar

Period FBDIX Return Category Return Low Category Return High Rank in Category (%)
2022 -12.8% -53.9% 11.7% 51.50%
2021 -15.3% -22.3% 18.5% 97.58%
2020 4.3% -4.7% 41.4% 54.84%
2019 5.4% -10.2% 13.1% 32.37%
2018 -4.0% -5.7% 26.9% 92.48%

NAV & Total Return History


FBDIX - Holdings

Concentration Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Assets 791 M 732 K 46.2 B 45.79%
Number of Holdings 81 3 507 45.50%
Net Assets in Top 10 455 M 2.18 K 21.6 B 40.00%
Weighting of Top 10 52.85% 12.3% 100.0% 23.00%

Top 10 Holdings

  1. Vertex Pharmaceuticals Inc 9.64%
  2. Amgen Inc 7.21%
  3. Regeneron Pharmaceuticals Inc 6.35%
  4. Regeneron Pharmaceuticals Inc 6.06%
  5. Regeneron Pharmaceuticals Inc 6.06%
  6. Regeneron Pharmaceuticals Inc 6.06%
  7. Regeneron Pharmaceuticals Inc 6.06%
  8. Regeneron Pharmaceuticals Inc 6.06%
  9. Regeneron Pharmaceuticals Inc 6.06%
  10. Regeneron Pharmaceuticals Inc 6.06%

Asset Allocation

Weighting Return Low Return High FBDIX % Rank
Stocks
98.86% 0.09% 106.13% 52.50%
Cash
0.58% -0.10% 99.91% 53.00%
Convertible Bonds
0.37% 0.00% 0.37% 0.50%
Other
0.18% -22.99% 3.38% 18.50%
Preferred Stocks
0.00% 0.00% 7.86% 13.00%
Bonds
0.00% 0.00% 12.39% 9.00%

Stock Sector Breakdown

Weighting Return Low Return High FBDIX % Rank
Healthcare
99.75% 26.56% 100.00% 57.00%
Basic Materials
0.25% 0.00% 14.83% 26.00%
Utilities
0.00% 0.00% 1.52% 7.00%
Technology
0.00% 0.00% 28.70% 15.00%
Real Estate
0.00% 0.00% 7.13% 12.50%
Industrials
0.00% 0.00% 7.02% 13.00%
Financial Services
0.00% 0.00% 8.43% 28.50%
Energy
0.00% 0.00% 0.00% 6.50%
Communication Services
0.00% 0.00% 12.28% 11.00%
Consumer Defense
0.00% 0.00% 25.73% 18.00%
Consumer Cyclical
0.00% 0.00% 14.20% 12.00%

Stock Geographic Breakdown

Weighting Return Low Return High FBDIX % Rank
US
91.28% 0.09% 104.41% 22.00%
Non US
7.58% 0.00% 45.40% 69.50%

FBDIX - Expenses

Operational Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.98% 0.08% 3.13% 40.59%
Management Fee 0.58% 0.00% 1.25% 34.74%
12b-1 Fee 0.25% 0.00% 1.00% 31.82%
Administrative Fee 0.15% 0.03% 0.25% 50.00%

Sales Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load 5.50% 0.00% 5.75% 30.77%
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FBDIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 47.30% 0.00% 238.00% 51.66%

FBDIX - Distributions

Dividend Yield Analysis

FBDIX Category Low Category High FBDIX % Rank
Dividend Yield 0.12% 0.00% 2.44% 20.00%

Dividend Distribution Analysis

FBDIX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

FBDIX Category Low Category High FBDIX % Rank
Net Income Ratio -0.58% -2.54% 1.92% 77.71%

Capital Gain Distribution Analysis

FBDIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Annually Annually

Distributions History

View More +

FBDIX - Fund Manager Analysis

Managers

Evan McCulloch


Start Date

Tenure

Tenure Rank

Sep 15, 1997

24.72

24.7%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Wendy Lam


Start Date

Tenure

Tenure Rank

Sep 01, 2018

3.75

3.8%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.

Akiva Felt


Start Date

Tenure

Tenure Rank

Jan 27, 2020

2.34

2.3%

Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.26 2.12